193 related articles for article (PubMed ID: 18561786)
1. [Concern about the safety of erythropoietin in cancer patients].
van der Lelie J
Ned Tijdschr Geneeskd; 2008 Apr; 152(16):920-2. PubMed ID: 18561786
[TBL] [Abstract][Full Text] [Related]
2. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
4. [Anaemia and radiation therapy].
Denis F; Lartigau E
Cancer Radiother; 2004 Nov; 8 Suppl 1():S14-23. PubMed ID: 15679242
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin for oncology supportive care.
McKinney M; Arcasoy MO
Exp Cell Res; 2011 May; 317(9):1246-54. PubMed ID: 21396935
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin in cancer: presumption of innocence?
Blau CA
Stem Cells; 2007 Aug; 25(8):2094-7. PubMed ID: 17464082
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin in cancer-related anemia.
Fenner MH; Ganser A
Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
Anand A; Anand A; Anand N
Cancer; 1996 May; 77(9):1960-1. PubMed ID: 8646701
[No Abstract] [Full Text] [Related]
9. [About the infrequent thrombotic events during erythropoietin therapy of anemia in ovarian cancer patients treated with chemotherapy].
Lehoczky O; Pulay T
Orv Hetil; 2007 Nov; 148(44):2081-5. PubMed ID: 17959551
[TBL] [Abstract][Full Text] [Related]
10. New Zealand cancer patients should have access to erythropoietin treatment.
Carter J; Clay J
N Z Med J; 2006 May; 119(1234):U1989. PubMed ID: 16718300
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin therapy in cancer-related anaemia, yes or no?
Herrmann R
Intern Med J; 2008 Oct; 38(10):749-50. PubMed ID: 19143876
[No Abstract] [Full Text] [Related]
12. Erythropoietin-stimulating agents in oncology.
Savona MR; Silver SM
Cancer J; 2008; 14(2):75-84. PubMed ID: 18391611
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic use of erythropoietin in dermatooncology.
Satzger I; Schenck F; Thol F; Ganser A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2007 Apr; 5(4):280-5. PubMed ID: 17376091
[TBL] [Abstract][Full Text] [Related]
14. [Use of erythropoietin in the treatment of cancer-related anemia].
Huang JX; Meng FJ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):877-8. PubMed ID: 22335959
[No Abstract] [Full Text] [Related]
15. Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?
Tefferi A
Mayo Clin Proc; 2007 Nov; 82(11):1316-8. PubMed ID: 17976350
[No Abstract] [Full Text] [Related]
16. Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy.
Krzakowski M;
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):705-13. PubMed ID: 18691854
[TBL] [Abstract][Full Text] [Related]
17. EPO in cancer anemia: benefits and potential risks.
Milano M; Schneider M
Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
[TBL] [Abstract][Full Text] [Related]
18. Is anemia of cancer different from chemotherapy-induced anemia?
Steensma DP
J Clin Oncol; 2008 Mar; 26(7):1022-4. PubMed ID: 18227523
[No Abstract] [Full Text] [Related]
19. Erythropoietic agents in chemotherapy-induced anemia: a review of recent therapeutic progress, issues, and concerns.
Boccia RV
Curr Hematol Rep; 2004 Nov; 3(6):397-405. PubMed ID: 15496272
[TBL] [Abstract][Full Text] [Related]
20. Studies explore factors that underlie varied responses to cancer drugs.
Hampton T
JAMA; 2008 Jul; 300(2):155-6. PubMed ID: 18612107
[No Abstract] [Full Text] [Related]
[Next] [New Search]
